Ascelia Pharma AB (CHIX:ACES) OCF Margin %: 0.00% (As of Mar. 2026)


CHIX:ACES Ascelia Pharma AB CHIX:ACES
37 GF Score
Price kr3.29
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB OCF Margin %?

Ascelia Pharma AB CHIX:ACES 37 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CHIX:ACES with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 960 Biotechnology companies, Ascelia Pharma AB ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Ascelia Pharma AB's Cash Flow from Operations for the three months ended in Mar. 2026 was kr-15.86 Mil. Ascelia Pharma AB's Revenue for the three months ended in Mar. 2026 was kr0.00 Mil. Therefore, Ascelia Pharma AB's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Ascelia Pharma AB's current OCF Yield % is -17.74%.

The historical rank and industry rank for Ascelia Pharma AB's OCF Margin % or its related term are showing as below:


CHIX:ACEs's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Ascelia Pharma AB OCF Margin % Related Terms

Ascelia Pharma AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB OCF Margin % Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:ACES
37GF Score
Ascelia Pharma AB CHIX:ACES
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Ascelia Pharma AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-72.252/0
= %

Ascelia Pharma AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-15.858/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Ascelia Pharma AB (CHIX:ACES) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Ascelia Pharma AB and its competitors. According to the industry distribution chart, Ascelia Pharma AB ranks #999999 out of 960 companies in the Biotechnology industry.
Is Ascelia Pharma AB's OCF Margin % too high?
Ascelia Pharma AB's current OCF Margin % is 0.00%. Based on the distribution chart, Ascelia Pharma AB ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascelia Pharma AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #999999 out of 960 companies for OCF Margin %. This places Ascelia Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (CHIX:ACES) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Ascelia Pharma AB's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Ascelia Pharma AB (CHIX:ACES), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACE:Sweden
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
37GF Score

Get the complete analysis for CHIX:ACES

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.29
Price